Pharmaceutical company Takeda is pioneering a technology-enabled, patient-centered future for plasma-derived therapies ...

Data-driven insights powered by advanced analytics and artificial intelligence (AI) help optimise project schedules, allocate ...

The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...

The finest minds from the pharma firmament will also be sharing insights on the changing landscape and on the new imperatives ...

In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...

Q4 2024 Earnings Call Transcript February 11, 2025 Royalty Pharma plc misses on earnings expectations. Reported EPS is ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus. NEW ...

Today, adoption of digital health faces some of the same barriers — scepticism, budget limitations, high expectations, and a ...

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

DMU will be part of a consortium laying the foundation for future medicines that are affordable, safe, effective, and ...

COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a ...